Hyperliquid Strategies (NASDAQ:PURR) Releases Quarterly Earnings Results

Hyperliquid Strategies (NASDAQ:PURR - Get Free Report) announced its quarterly earnings data on Thursday, May 7th. The company reported $1.01 EPS for the quarter, FiscalAI reports. The business had revenue of $2.63 million for the quarter.

Here are the key takeaways from Hyperliquid Strategies' conference call:

• The company holds roughly 18.8–20M HYPE tokens and reported $202.4M of treasury strategy income in Q3 (driven by a $198.4M unrealized HYPE gain), while staking all tokens and earning $2.6M in staking revenue.
• HIP-3 (real‑world asset perps) has rapidly gained traction—five of Hyperliquid’s top 10 trading pairs are real‑world assets and an oil contract hit $710M in 24‑hour volume, attracting TradFi interest.
• Hyperliquid will launch its own validator on May 11 in partnership with Unit/Trade XYZ, intended to deepen ecosystem alignment and create new revenue streams for the company.
• HIP‑4 (outcome/prediction markets) plus Builder Codes are live as proofs‑of‑concept, enabling permissionless third‑party deployers and opening addressable markets including options, insurance and pre‑IPO trading.
• The company spent about $160M acquiring HYPE, lowering cash to $113.1M, reported a nine‑month net loss of $165.4M (including a one‑time IPR&D write‑off), and carries a sizable deferred tax liability that would crystallize if tokens were sold.

Hyperliquid Strategies Trading Up 12.4%

Shares of NASDAQ PURR opened at $7.79 on Wednesday. The firm has a 50 day moving average price of $5.90. Hyperliquid Strategies has a 52 week low of $3.01 and a 52 week high of $7.94. The company has a market cap of $1.05 billion, a PE ratio of -1.06 and a beta of 1.44.

Analysts Set New Price Targets

Several analysts recently commented on PURR shares. Weiss Ratings started coverage on shares of Hyperliquid Strategies in a report on Monday, March 2nd. They set a "sell (e)" rating for the company. Chardan Capital increased their target price on shares of Hyperliquid Strategies from $8.45 to $9.75 and gave the stock a "buy" rating in a research report on Wednesday. Wall Street Zen raised shares of Hyperliquid Strategies to a "hold" rating in a research note on Saturday, February 21st. Maxim Group began coverage on shares of Hyperliquid Strategies in a report on Friday, April 24th. They set a "buy" rating and a $10.00 price target on the stock. Finally, Cantor Fitzgerald upped their price target on shares of Hyperliquid Strategies from $6.00 to $8.00 and gave the stock an "overweight" rating in a research note on Monday, May 11th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Hyperliquid Strategies has an average rating of "Moderate Buy" and a consensus target price of $9.25.

Institutional Trading of Hyperliquid Strategies

Large investors have recently made changes to their positions in the stock. Galaxy Group Investments LLC acquired a new stake in Hyperliquid Strategies in the 4th quarter valued at approximately $15,167,000. Pantera Capital Partners LP acquired a new position in shares of Hyperliquid Strategies during the fourth quarter worth approximately $14,545,000. Feynman Point Asset Management LLC acquired a new position in shares of Hyperliquid Strategies during the fourth quarter worth approximately $14,431,000. GM Advisory Group LLC bought a new stake in shares of Hyperliquid Strategies in the fourth quarter valued at approximately $2,946,000. Finally, Saba Capital Management L.P. bought a new stake in shares of Hyperliquid Strategies in the fourth quarter valued at approximately $2,494,000. Institutional investors own 9.45% of the company's stock.

Hyperliquid Strategies Company Profile

Hyperliquid Strategies Inc is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. Hyperliquid Strategies Inc, formerly known as Sonnet BioTherapeutics Holdings Inc, is based in NEW YORK.